Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home








COVID-19 VaST Work Group Report – March 29, 2021						Print
																Related Pages
										The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical (VaST) Work Group has reviewed post-authorization Covid-19 vaccine safety data on a weekly basis since the start of the U.S. vaccination program.  Updates of VaST activities have been presented at ACIP meetings that are open to the public on January 27 and March 1.  The VaST Work Group provides this written update to the public, in the absence of a scheduled ACIP meeting this month.
As of March 29, 2021, there had been a total of 143 million doses administered in the United States (Pfizer-BioNTech: 72,981,111; Moderna: 67,249,447; Johnson & Johnson/Janssen: 3,090,712; Unknown: 141,421).  The VaST Subgroup has reviewed data from multiple U.S. safety monitoring surveillance systems conducted by different federal agencies and other partners including:
**Passive surveillance systems**
Vaccine Adverse Event Reporting System (VAERS)
Department of Veterans Administration (VA) Adverse Drug Events Reporting System (ADERS)
Department of Defense VAERS reports
**Active surveillance systems**
v-safe
Vaccine Safety Datalink (VSD) Rapid Cycle Analysis
Department of VA Active Surveillance System
Food and Drug Administration (FDA) Centers for Medicare and Medicaid Services (CMS) Rapid Cycle Analysis
**Studies and registry**
v-safe pregnancy registry
VSD Mortality Study
Vaccine safety monitoring in skilled nursing facilities
Summary of VaST Work Group observations as of 03/29/2021:
Rare cases of anaphylaxis following COVID-19 vaccination were identified early in the vaccination program; FDA and CDC revised educational materials and clinical guidance.
Consistent with clinical trial data, local and systemic reactions are commonly reported following vaccination for all individuals and for pregnant women.
Data from passive systems suggest that case reports are not higher than expected based on rates of all-cause morbidity and mortality.
Pregnancy and birth outcomes following vaccination appear consistent with rates reported in the literature.
In the active surveillance systems (rapid cycle analyses), pre-specified outcomes are actively monitored; no statistical signals have been reported to date with >10 million doses administered across systems.
Adverse events following COVID-19 vaccination are being monitored through passive and active systems. VaST will continue to update the ACIP COVID-19 vaccines workgroup, ACIP secretariat and ACIP on a regular basis.Past reports from the VaST Work Group to ACIPVaST assessement of safety data
2022
February 4, 2022pdf icon
April 20, 2022pdf icon
May 19, 2022pdf icon2021
January 27, 2021pdf icon
March 1, 2021pdf icon
April 14, 2021pdf icon
April 23, 2021pdf icon
May 12, 2021pdf icon
June 23, 2021pdf icon
July 22, 2021pdf icon
August 30, 2021pdf icon
September 22, 2021pdf icon
October 21, 2021pdf icon
November 19, 2021pdf icon
December 16, 2021pdf icon
							
					
							Last Reviewed:  May 20, 2021						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue